


CLAIMS

1. A compound of Formula:



I

or a pharmaceutically acceptable salt thereof,

5 wherein:

A is selected from $-C(=O)C(=O)-$, $-C(=O)Z-$, $-C(=S)Z-$, $C(=NR^5)Z-$, and $-S(O)_2-$;

wherein Z is $-CH_2-$, $-CH(OH)-$, $-CH(OC(=O)R^{11})-$, $-CH(NH_2)-$, $-CH(CH_2(OH))-$, $-CH(CH(C_1-C_4 \text{ alkyl})(OH))-$, or $-CH(C(C_1-C_4 \text{ alkyl})(C_1-C_4 \text{ alkyl})(OH))-$;

10 R^1 is selected from C_1-C_{20} alkyl and $-C_1-C_{20}$ alkoxy, C_3-C_8 cycloalkyl, (C_4-C_8) cycloalkenyl, (C_5-C_{11}) bi- or tricycloalkyl, (C_7-C_{11}) bi- or tricycloalkenyl, (3-8 membered) heterocycloalkyl, (C_6-C_{14}) aryl, or (5-14 membered) heteroaryl, wherein said alkyl and alkoxy each optionally contains from one to five double or triple bonds, and wherein each hydrogen atom of said alkyl and alkoxy is optionally replaced with a fluorine;

15 wherein when R^1 is alkyl or alkoxy, R^1 is optionally substituted with from one to three substituents R^{1a} , and wherein when R^1 is cycloalkyl, cycloalkenyl, bi- or tricycloalkyl, bi- or tricycloalkenyl, heterocycloalkyl, aryl, or heteroaryl, then R^1 is optionally substituted with from one to three substituents R^{1b} ;

20 R^{1a} is in each instance independently selected from $-OH$, $-C_1-C_6$ alkyl independently optionally containing from one to three double or triple bonds, $-C_1-C_6$ alkoxy independently optionally containing from one to three double or triple bonds, $-Cl$, $-F$, $-Br$, $-I$, $-CN$, $-NO_2$, $-NR^9R^{10}$, $-C(=O)NR^9R^{10}$, $-S(O)_nNR^9R^{10}$, $-C(=O)R^{11}$, $-S(O)_nR^{11}$, $-C(=O)OR^{12}$, $-C_3-C_8$ cycloalkyl, $-C_4-C_8$ cycloalkenyl, $-(C_5-C_{11})$ bi- or tricycloalkyl, $-(C_7-C_{11})$ bi- or tricycloalkenyl, $-(3-8 \text{ membered})$ heterocycloalkyl, $-(C_6-C_{14})$ aryl, $-(5-14 \text{ membered})$ heteroaryl, $-(C_6-C_{14})$ aryloxy, and $-(5-14 \text{ membered})$ heteroaryloxy, wherein said alkyl, alkoxy, cycloalkyl, cycloalkenyl, bi- or tricycloalkyl, 25 bi- or tricycloalkenyl, heterocycloalkyl, aryl, heteroaryl, aryloxy, and heteroaryloxy are each independently optionally substituted with from one to three substituents R^{1b} ;

30 R^{1b} is in each instance independently selected from $-Cl$, $-F$, $-Br$, $-I$, $-CN$, $-NO_2$, $-(C_{zero}-C_4 \text{ alkylene})-NR^9R^{10}$, $-(C_{zero}-C_4 \text{ alkylene})-C(=O)NR^9R^{10}$, $-(C_{zero}-C_4 \text{ alkylene})-C(=O)R^{11}$, $-(C_{zero}-C_4 \text{ alkylene})-C(=O)OR^{12}$, $-(C_{zero}-C_4 \text{ alkylene})-S(O)_nR^{11}$, $-(C_{zero}-C_4 \text{ alkylene})-S(O)_nNR^9R^{10}$, $-(C_{zero}-C_4 \text{ alkylene})-OH$, $-C_1-C_6$ alkyl independently optionally containing from one to three double or triple bonds, $-C_1-C_6$ alkoxy independently optionally containing from one to three double or triple bonds, $-C_1-C_6$ hydroxyalkyl, $-(C_6-C_{14})$ aryloxy, $-(5-14 \text{ membered})$ heteroaryloxy,

-(C₆-C₁₄) aryl, -(5-15 membered) heteroaryl, and -C₁-C₆ alkyl independently optionally containing from one to three double or triple bonds and independently substituted with from one to six atoms independently selected from F, Cl, Br, and I;

R² is selected from -H, -C₁-C₄ alkyl optionally containing one or two double or triple bonds, -C(=O)(C₁-C₄ alkyl), -C₆-C₁₀ aryl, -SO₂-(C₆-C₁₀ aryl), and -SO₂-CH₂-(C₆-C₁₀ aryl), and R² is optionally substituted with from one to three substituents R^{1b};

R³ is selected from C₁-C₆ alkyl, -C₂-C₆ alkenyl, -C₂-C₆ alkynyl, -(C_{zero}-C₄ alkylene)-(C₃-C₆ cycloalkyl), and -(C_{zero}-C₄ alkylene)-(C₃-C₆ cycloalkenyl), wherein said alkyl, alkenyl and alkynyl are each optionally substituted with a substituent selected from -OH, C₁-C₄ alkoxy, and -S-(C₁-C₄ alkyl);

R⁴ is H, D, F, or C₁-C₄ alkyl;

or R³ and R⁴ may together optionally form a cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, morpholino, piperidino, or perhydro-2H-pyran moiety, wherein said moiety formed by R³ and R⁴ is optionally substituted with one to three substituents independently selected from -OH, -Cl, -F, -CN, -CF₃, methyl, ethyl, methoxy, ethoxy, allyl, and -OCF₃;

R⁵ is selected from -H, -C₁-C₆ alkyl optionally substituted with from one to three R^{1a} groups, and -C₆-C₁₀ aryl optionally substituted with from one to three R^{1a} groups;

or R⁵ and R¹ may together optionally form a five to fourteen membered heteroaryl ring or a five to eight membered heterocycloalkyl ring, wherein said heteroaryl or heterocycloalkyl ring optionally contains one or two further heteroatoms selected from N, O, and S, and wherein said heterocycloalkyl ring optionally contains from one to three double bonds, and wherein said heteroaryl or heterocycloalkyl ring is optionally substituted from one to three R^{1b} substituents;

R⁶ is selected from -H, -C₁-C₂₀ alkyl, -Cl, -F, -Br, -I, -CN, -CF₃, -C(=O)R¹¹, -C(=O)OR¹², -S(O)_nNR⁹R¹⁰, -S(O)_nR¹¹, -C(=NR⁹)R¹⁵, -(C₃-C₁₂) cycloalkyl, -(C₄-C₁₂) cycloalkenyl, and -C₆-C₁₀ aryl, wherein said alkyl, alkylene, cycloalkyl, cycloalkenyl, and aryl of R⁶ are each optionally substituted with from one to three R^{1b} substituents;

R⁷ is selected from H, -Cl, -F, -Br, -I, -CN, -NO₂, -NR¹⁴R¹⁵, -CF₃, -C(=O)NR¹⁴R¹⁵, -C(=O)R¹³, -S(O)_nR¹³, -C(=O)OR¹³, -C(=NR⁹)R¹⁵, -S(O)_nNR¹⁴R¹⁵, -C₁-C₂₀ alkyl, -C₁-C₂₀ alkoxy, -(C_{zero}-C₄ alkylene)-(C₃-C₁₂ cycloalkyl), -(C_{zero}-C₄ alkylene)-((C₄-C₁₂)cycloalkenyl), -(C_{zero}-C₄ alkylene)-((C₅-C₂₀)bi- or tricycloalkyl), -(C_{zero}-C₄ alkylene)-((C₇-C₂₀)bi- or tricycloalkenyl), -(C_{zero}-C₄ alkylene)-((3-12 membered) heterocycloalkyl), -(C_{zero}-C₄ alkylene)-((7-20 membered) heterobi- or heterotricycloalkyl), -(C_{zero}-C₄ alkylene)-((C₆-C₁₄)aryl), and -(C_{zero}-C₄ alkylene)-((5-15 membered) heteroaryl); wherein R⁷ is optionally substituted with from one to three substituents independently selected from R^{1a}, -(CH₂)₁₋₁₀NR⁹R¹⁰, -C₃-C₁₂ cycloalkyl, -((4-12 membered) heterocycloalkyl), -(C₆-C₁₄) aryl, -((5-15 membered) heteroaryl), -(4-12 membered) heterocycloalkoxy, -(C₆-C₁₂) aryloxy and -((5-12 membered)

heteroaryloxy); said cycloalkyl, cycloalkenyl, bi- or tricycloalkyl, bi- or tricycloalkenyl, heterocycloalkyl, aryl, and heteroaryl of R^7 are each optionally and independently substituted with from one to six F; said alkyl, alkoxy, and alkylene of R^7 each optionally contains from one to five double or triple bonds; and each hydrogen atom of said alkyl, alkoxy, and alkylene of R^7 is independently optionally replaced with a fluorine;

or R^6 and R^7 or R^7 and its proximate nitrogen atom may together optionally form a $-(C_6-C_{10})$ aryl ring, $-(C_6-C_8)$ cycloalkyl or cycloalkenyl ring, a five to eight membered heterocycloalkyl or heterocycloalkenyl ring, a $-(C_{10}-C_{14})$ membered bicycloalkyl or bicycloalkenyl ring, or a ten to fourteen membered bicycloheteroalkyl or bicycloheteroalkenyl ring fused to the pyrazole ring of Formula I, wherein from one to three members of said heterocycloalkyl and heterocycloalkenyl rings, and from one to five members of said bicycloheteroalkyl and bicycloheteroalkenyl rings are selected independently from N, O and S, and wherein said aryl, cycloalkyl, cycloalkenyl, heterocycloalkyl, heterocycloalkenyl, bicycloalkyl, bicycloalkenyl, bicycloheteroalkyl, and bicycloheteroalkenyl rings optionally are substituted with from one to three R^{1b} groups;

R^8 is selected from -H, $-C_1-C_4$ alkyl, -Cl, -F, -Br, -I, -CN, $-CF_3$, $-C(=O)R^{11}$, $-C(=O)OR^{12}$, and $-C_6-C_{10}$ aryl, with the proviso that the pyrazole ring is always aromatic and that R^8 is attached to either ring nitrogen;

R^9 and R^{10} are each independently selected from -H, -OH, $-C_1-C_6$ alkyl independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with a fluorine, $-C_1-C_6$ alkoxy independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with a fluorine, $-C(=O)R^{11}$, $-S(O)_nR^{11}$, $-C(=O)OR^{12}$, $-S(O)_nNR^{11}R^{12}$, $-(C_{zero}-C_4 \text{ alkylene})-(C_3-C_8 \text{ cycloalkyl})$, $-(C_{zero}-C_4 \text{ alkylene})-(C_4-C_8 \text{ cycloalkenyl})$, $-(C_{zero}-C_4 \text{ alkylene})-((C_5-C_{11})\text{bi- or tricycloalkyl})$, $-(C_{zero}-C_4 \text{ alkylene})-((C_7-C_{11})\text{bi- or tricycloalkenyl})$, $-(C_{zero}-C_4 \text{ alkylene})-(C_6-C_{14} \text{ aryl})$, $-(C_{zero}-C_4 \text{ alkylene})-(3-8 \text{ membered heterocycloalkyl})$, and $-(C_{zero}-C_4 \text{ alkylene})-(5-14 \text{ membered heteroaryl})$, wherein said cycloalkyl, cycloalkenyl, bi-or tricycloalkyl, bi- or tricycloalkenyl, aryl, heterocycloalkyl, and heteroaryl are each optionally independently substituted with from one to three substituents independently selected from -Cl, -F, -Br, -I, -CN, $-NO_2$, $-NR^{14}R^{15}$, $-C(=O)NR^{14}R^{15}$, $-C(=O)R^{11}$, $-C(=O)OR^{12}$, $-S(O)_nR^{11}$, $-S(O)_nNR^{14}R^{15}$, -OH, $-C_1-C_6$ alkyl independently optionally containing from one to three double or triple bonds, $-C_1-C_6$ alkoxy independently optionally containing from one to three double or triple bonds, $-C_1-C_6$ hydroxyalkyl, $-(C_6-C_{14})$ aryloxy, $-(5-14 \text{ membered})$ heteroaryloxy, $-(C_{zero}-C_4)-((C_6-C_{14}) \text{ aryl})$, $-(C_{zero}-C_4)-(5-14 \text{ membered heteroaryl})$, and $-C_1-C_6$ alkyl independently optionally containing from one to three double or triple bonds and independently substituted with from one to six atoms independently selected from F, Cl, Br, and I;

EXPRESS MAIL NO. EL 874 866 426 05

or NR^9R^{10} can independently optionally form a heterocycloalkyl moiety of from four to seven ring members, said heterocycloalkyl moiety independently optionally comprising one or two further heteroatoms independently selected from N, O, and S, and independently optionally containing from one to three double bonds, and said heterocycloalkyl moiety independently optionally substituted with from one to three substituents independently selected from -Cl, -F, -Br, -I, -CN, -NO₂, -NR¹⁴R¹⁵, -C(=O)NR¹⁴R¹⁵, -C(=O)R¹¹, -C(=O)OR¹², -S(O)_nR¹¹, -S(O)_nNR¹⁴R¹⁵, -OH, -C₁-C₆ alkyl independently optionally containing from one to three double or triple bonds, -C₁-C₆ alkoxy independently optionally containing from one to three double or triple bonds, -C₁-C₆ hydroxyalkyl independently optionally containing from one to three double or triple bonds, -(C₆-C₁₄) aryloxy, -(5-14 membered) heteroaryloxy, -(C_{zero}-C₄)-(C₆-C₁₄) aryl, -(C_{zero}-C₄)-(5-14 membered heteroaryl), and -C₁-C₆ alkyl independently optionally containing from one to three double or triple bonds and independently substituted with from one to six atoms independently selected from F, Cl, Br, and I;

R¹¹ and R¹² are each independently selected from H, -C₁-C₆ alkyl, -(C_{zero}-C₄ alkylene)-(C₃-C₈ cycloalkyl), -(C_{zero}-C₄ alkylene)-(C₄-C₈ cycloalkenyl), -(C_{zero}-C₄ alkylene)-((C₅-C₁₁)bi- or tricycloalkyl), and -(C_{zero}-C₄ alkylene)-((C₇-C₁₁)bi- or tricycloalkenyl), -(C_{zero}-C₄ alkylene)-(C₆-C₁₀ aryl), -(C_{zero}-C₄ alkylene)-((3-8 membered) heterocycloalkyl), and -(C_{zero}-C₄ alkylene)-((5-14 membered) heteroaryl), and R¹¹ and R¹² are independently optionally substituted with from one to three R^{1b};

R¹³ is selected from H, -C₁-C₆ alkyl optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with a fluorine, -(C_{zero}-C₄ alkylene)-(C₃-C₁₂ cycloalkyl), -(C_{zero}-C₄ alkylene)-(C₄-C₁₂ cycloalkenyl), -(C_{zero}-C₄ alkylene)-((C₅-C₂₀)bi- or tricycloalkyl), and -(C_{zero}-C₄ alkylene)-((C₇-C₂₀)bi- or tricycloalkenyl), -(C_{zero}-C₄ alkylene)-(C₆-C₁₄ aryl), -(C_{zero}-C₄ alkylene)-((3-12 membered) heterocycloalkyl), -(C_{zero}-C₄ alkylene)-((7-20 membered) heterobi- or heterotricycloalkyl), and -(C_{zero}-C₄ alkylene)-((5-14 membered) heteroaryl), and R¹³ is optionally substituted with from one to three substituents R^{1b};

R¹⁴ and R¹⁵ are each independently selected from -H, -C₁-C₂₀ alkyl independently optionally containing from one to five double or triple bonds and wherein each hydrogen is independently optionally replaced with a fluorine, -C(=O)R¹¹, -S(O)_nR¹¹, -C(=O)OR¹², -S(O)_nNR¹¹R¹², -(C_{zero}-C₄ alkylene)-(C₃-C₁₂ cycloalkyl), -(C_{zero}-C₄ alkylene)-(C₄-C₁₂ cycloalkenyl), -(C_{zero}-C₄ alkylene)-((C₅-C₂₀)bi- or tricycloalkyl), -(C_{zero}-C₄ alkylene)-((C₇-C₂₀)bi- or tricycloalkenyl), -(C_{zero}-C₄ alkylene)-(C₆-C₁₄ aryl), -(C_{zero}-C₄ alkylene)-(3-8 membered heterocycloalkyl), and -(C_{zero}-C₄ alkylene)-(5-14 membered heteroaryl), wherein said cycloalkyl, cycloalkenyl, bi- or tricycloalkyl, bi- or tricycloalkenyl, aryl, heterocycloalkyl, and heteroaryl are each independently optionally substituted with from one to three substituents independently selected from -C₁-C₆ alkyl independently optionally containing from one to three double or

triple bonds and wherein each hydrogen is independently optionally replaced with fluorine, -Cl, -F, -Br, -I, -CN, -NO₂, -NH₂, -OH, -C(=O)H, -S(O)_nH, -C(=O)OH, -C(=O)NH₂, -S(O)_nNH₂, -C₁-C₆ alkoxy independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with fluorine, -C₁-C₆ hydroxyalkyl independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with fluorine, -(5-14 membered) heteroaryloxy, -(C₆-C₁₄ aryloxy), -(C_{zero}-C₄ alkylene)-(C₆-C₁₄ aryl), -(C_{zero}-C₄ alkylene)-((5-14 membered) heteroaryl), and -C₁-C₆ alkyl independently substituted with from one to six atoms independently selected from F, Cl, Br, and I and independently optionally containing from one to three double or triple bonds;

or NR¹⁴R¹⁵ can independently optionally form a heterocycloalkyl moiety of from four to seven ring members, said heterocycloalkyl moiety independently optionally comprising one or two further heteroatoms independently selected from N, O, and S, and independently optionally containing from one to three double bonds, and said heterocycloalkyl moiety independently optionally substituted with from one to three substituents independently selected from -C₁-C₆ alkyl independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with fluorine, -Cl, -F, -Br, -I, -CN, -NO₂, -NH₂, -OH, -C(=O)H, -S(O)_nH, -C(=O)OH, -C(=O)NH₂, -S(O)_nNH₂, -C₁-C₆ alkoxy independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with fluorine, -C₁-C₆ hydroxyalkyl independently optionally containing from one to three double or triple bonds and wherein each hydrogen is independently optionally replaced with a fluorine, -(5-14 membered) heteroaryloxy, -(C₆-C₁₄ aryloxy), -(C_{zero}-C₄ alkylene)-(C₆-C₁₄ aryl), -(C_{zero}-C₄ alkylene)-((5-14 membered) heteroaryl), and -C₁-C₆ alkyl independently optionally containing from one to three double or triple bonds and independently substituted with from one to six atoms independently selected from F, Cl, Br, and I; and

n is in each instance an integer independently selected from zero, 1, 2, and 3.

2. A compound according to claim 1, wherein A is -C(=O)Z- or -C(=O)C(=O)-.
3. A compound according to claim 2, wherein Z is -CH₂- or -CH(OH)-.
4. A compound according to any of claim 1, wherein R³ is allyl, methyl, ethyl, *n*-propyl, *n*-butyl, *i*-butyl, *s*-butyl, or -CH₂CH₂SCH₃.
5. A compound according to claim 1, wherein R⁶ is selected from hydrogen, methyl, ethyl, -F, -Cl, -Br, and -CF₃.
6. A compound according to claim 1 wherein R¹ is -C₂-C₁₂ alkyl, C₃-C₈ cycloalkyl, (C₅-C₈)cycloalkenyl, -(C₅-C₁₁)bi- or tricycloalkyl, -(C₇-C₁₁)bi- or tricycloalkenyl, (3-8 membered) heterocycloalkyl, -(C₆-C₁₀)aryl, -(5-10 membered) heteroaryl, or C₁-C₄ alkyl substituted with R^{1a} wherein R^{1a} is -(C₆-C₁₀)aryl or -(5-10 membered) heteroaryl.

7. A compound according to claim 1 wherein R^1 is straight-chain C_2 - C_{10} alkyl or branched C_3 - C_{10} alkyl.

8. A compound according to claim 1, wherein R^1 is C_3 - C_{10} alkyl comprising a tertiary carbon or C_4 - C_{10} alkyl comprising a quaternary carbon.

5 9. A compound according to claim 1, wherein R^1 is selected from phenyl, thienyl, and pyridyl, optionally and independently substituted with one or two substituents R^{1b} .

10 10. A compound according to claim 1, wherein R^7 is selected from -H, $-C_1$ - C_{12} alkyl optionally containing from one to five double bonds and wherein each hydrogen is independently optionally replaced with a fluorine, $-C_1$ - C_{20} alkoxy optionally containing from one to five double bonds and wherein each hydrogen is independently optionally replaced with a fluorine, -F, -Cl, -Br, -I, -CN, -NO₂, $-(C_3$ - $C_{12})$ cycloalkyl optionally substituted with from one to six fluorine, $-((3$ -12 membered) heterocycloalkyl) optionally substituted with from one to six fluorine, $-(C_6$ - $C_{14})$ aryl, $-((5$ -15 membered) heteroaryl), -CHO, $-C(=O)(C_1$ - C_{15} alkyl), $-C(=O)((5$ -12 membered) heterocycloalkyl), $-C(=O)(C_6$ - C_{14} aryl), $-C(=O)((5$ -15 membered) heteroaryl), $-C(=O)(C_5$ - C_{12} cycloalkyl), $-C(=O)O(C_1$ - C_8 alkyl), $-C(=O)N(C_1$ - C_{10} alkyl)(C_1 - C_{10} alkyl), $-C(=O)N(C_1$ - C_{10} alkyl)(C_6 - C_{10} aryl), $-C(=O)NH(C_6$ - C_{10} aryl), $-C(=O)N(C_1$ - C_{10} alkyl)((5-10 membered) heteroaryl), $-C(=O)NH((5$ -10 membered) heteroaryl), $-C(=O)N(C_1$ - C_{10} alkyl)((5-10 membered) heterocycloalkyl), $-C(=O)NH((5$ -10 membered) heterocycloalkyl), $-C(=O)N(C_1$ - C_{10} alkyl)(C_5 - C_{10} cycloalkyl), $-C(=O)NH(C_5$ - C_{10} cycloalkyl), $-S(O)_n(C_1$ - C_{15} alkyl), $-S(O)_n(C_5$ - C_{12} cycloalkyl), $-S(O)_n(C_6$ - C_{15} aryl), $-S(O)_n((5$ -10 membered) heteroaryl), wherein said alkyl, cycloalkyl, heterocycloalkyl, aryl and heteroaryl are each optionally independently substituted with from one to three substituents independently selected from -F, -Cl, -Br, -I, -OH, $-C_1$ - C_6 alkoxy independently optionally containing from one to three double or triple bonds, $-NR^9R^{10}$, $-(CH_2)_{1-10}NR^9R^{10}$, $-C(=O)R^{11}$, $-S(O)_nR^{11}$, $-C(=O)OR^{11}$, $-C(=O)NR^9R^{10}$, $-S(O)_nNR^9R^{10}$, $-(C_3$ - $C_{12})$ cycloalkyl, $-((4$ -12 membered) heterocycloalkyl), $-(C_6$ - $C_{15})$ aryl, $-((5$ -15 membered) heteroaryl), $-((4$ -12 membered) heterocycloalkoxy), $-(C_6$ - $C_{12})$ aryloxy and $-((6$ -12 membered) heteroaryloxy).

11. A compound according to claim 10, wherein R^7 is selected from $-C_1$ - C_{12} alkyl optionally comprising from one to five double bonds and wherein each hydrogen is independently optionally replaced with a fluorine, $-(C_3$ - $C_{12})$ cycloalkyl optionally substituted with from one to six fluorine, and $-((3$ -12 membered) heterocycloalkyl) optionally substituted with from one to six fluorine, wherein said alkyl, cycloalkyl and heterocycloalkyl are each optionally independently substituted with from one to three substituents independently selected from -OH, $-C_1$ - C_6 alkoxy independently optionally containing from one to three double or triple bonds, $-NR^9R^{10}$, $-(CH_2)_{1-6}NR^9R^{10}$, $-C(=O)R^{11}$, $-C(=O)OR^{11}$, $-C(=O)NR^9R^{10}$, $-S(O)_nNR^9R^{10}$, $-(C_6$ - $C_{15})$ aryl, $-((5$ -15 membered) heteroaryl), $-((4$ -12 membered) heterocycloalkoxy), $-(C_6$ - $C_{12})$ aryloxy and $-((6$ -12 membered) heteroaryloxy).

12. A compound according to claim 1 selected from the group consisting of:
- 2-(2-benzo[b]thiophen-4-yl-acetyl-amino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
N-(5-phenyl-2H-pyrazol-3-yl)-2-(2-thiophen-2-yl-acetyl-amino)-propionamide;
2-[2-(4-fluoro-phenyl)-2-hydroxy-acetyl-amino]-N-(5-phenyl-2H-pyrazol-3-yl)-
5 propionamide;
2-[2-(4-chloro-phenyl)-2-hydroxy-acetyl-amino]-N-(5-phenyl-2H-pyrazol-3-yl)-
propionamide;
N-(5-phenyl-2H-pyrazol-3-yl)-2-(2-m-tolyl-acetyl-amino)-propionamide;
2-[2-(2,5-difluoro-phenyl)-acetyl-amino]-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
10 2-[2-hydroxy-2-(4-trifluoromethyl-phenyl)-acetyl-amino]-N-(5-phenyl-2H-pyrazol-3-yl)-
propionamide;
2-(2-fluoro-2-phenyl-acetyl-amino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
N-(5-phenyl-2H-pyrazol-3-yl)-2-[2-(4-trifluoromethyl-phenyl)-acetyl-amino]-
propionamide;
15 2-[2-(2-fluoro-5-trifluoromethyl-phenyl)-acetyl-amino]-N-(5-phenyl-2H-pyrazol-3-yl)-
propionamide;
2-[2-(4-fluoro-3-trifluoromethyl-phenyl)-acetyl-amino]-N-(5-phenyl-2H-pyrazol-3-yl)-
propionamide;
N-(5-phenyl-2H-pyrazol-3-yl)-2-[2-(2-trifluoromethoxy-phenyl)-acetyl-amino]-
20 propionamide;
2-[2-(3-phenoxy-phenyl)-acetyl-amino]-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
N-(5-phenyl-2H-pyrazol-3-yl)-2-[2-(4-trifluoromethoxy-phenyl)-acetyl-amino]-
propionamide;
2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetyl-amino]-N-(5-phenyl-2H-pyrazol-3-yl)-
25 propionamide;
acetic acid (3,5-difluoro-phenyl)-[1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-
ethylcarbamoyl]-methyl ester;
2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetyl-amino]-N-(5-phenyl-2H-pyrazol-3-yl)-
propionamide;
30 2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetyl-amino]-N-(5-phenyl-2H-pyrazol-3-yl)-
propionamide;
2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetyl-amino]-N-(5-phenyl-2H-pyrazol-3-yl)-
butyramide;
2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetyl-amino]-N-(5-phenyl-2H-pyrazol-3-yl)-
35 butyramide;
N-(5-phenyl-2H-pyrazol-3-yl)-2-(2-pyridin-3-yl-acetyl-amino)-butyramide;
N-(5-phenyl-2H-pyrazol-3-yl)-2-(2-pyridin-2-yl-acetyl-amino)-butyramide;

- 2-[2-(5-bromo-pyridin-3-yl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
2-(3-cyclopentyl-propionylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
2-phenyl-cyclopropanecarboxylic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-
propyl]-amide;
- 5 N-[1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-succinamic acid methyl ester;
3,3-dimethyl-N-[1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-butyramide;
dodecanoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-amide;
2-phenylacetylamino-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
hexanoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-amide;
- 10 heptanoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-amide;
2-(3-chloro-propionylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
2-(3-phenyl-propionylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
3-methyl-N-[1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-butyramide;
decanoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-amide;
- 15 2-butyrylamino-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
5-chloro-pentanoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-amide;
2-[2-(3-phenoxy-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
3-[[1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propylcarbamoyl]-methyl]-piperidine-1-
carboxylic acid tert-butyl ester;
- 20 N-(5-phenyl-2H-pyrazol-3-yl)-2-[2-(3-trifluoromethyl-phenyl)-acetylamino]-butyramide;
2-[2-(3-iodo-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
2-[2-(3-chloro-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
4-methylsulfanyl-2-[2-(3-phenoxy-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-
butyramide;
- 25 2-hydroxy-4-methyl-pentanoic acid [3-methylsulfanyl-1-(5-phenyl-2H-pyrazol-3-
ylcarbamoyl)-propyl]-amide;
2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-4-methylsulfanyl-N-(5-phenyl-2H-
pyrazol-3-yl)-butyramide;
2-acetylamino-4-methylsulfanyl-N-(5-phenyl-2H-pyrazol-3-yl)- butyramide;
- 30 5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic
acid ethyl ester;
5-[2-(2-hydroxy-4-methyl-pentanoylamino)-butyrylamino]-1H-pyrazole-3-
carboxylic acid ethyl ester;
- 35 5-{2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-butyrylamino}-1H-pyrazole-3-
carboxylic acid ethyl ester;
2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(5-hydroxymethyl-2H-pyrazol-3-yl)-
butyramide;

- 2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(5-hydrazinocarbonyl-2H-pyrazol-3-yl)-butyramide;
- 2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-[5-(5-phenyl-4H-[1,2,4]triazol-3-yl)-2H-pyrazol-3-yl]-butyramide;
- 5 2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(4-oxo-4,5-dihydro-pyrazolo[1,5-d][1,2,4]triazin-2-yl)-butyramide;
- 2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(4-methoxy-7-phenyl-pyrazolo[1,5-d][1,2,4]triazin-2-yl)-butyramide;
- 10 5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid amide;
- 2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(4-oxo-7-phenylsulfanylmethyl-4,5-dihydro-pyrazolo[1,5-d][1,2,4]triazin-2-yl)-butyramide;
- 5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid methylamide;
- 15 5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid (1-ethyl-propyl)-amide;
- 5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid butyl-ethyl-amide;
- 5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid cyclopropylmethyl-amide;
- 20 2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-[5-(morpholine-4-carbonyl)-2H-pyrazol-3-yl]-butyramide;
- 2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-[5-(pyrrolidine-1-carbonyl)-2H-pyrazol-3-yl]-butyramide;
- 25 5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide;
- 5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid sec-butyl-amide;
- 5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid ethyl-(2-hydroxy-ethyl)-amide;
- 30 5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid cyclohexyl-ethyl-amide;
- 5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid diallylamide;
- 35 2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;

- 2-[2-(3,5-difluoro-phenyl)-acetylamino]-3-methyl-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 2-[2-(3,5-difluoro-phenyl)-acetylamino]-3-methyl-pentanoic acid (5-butyl-2H-pyrazol-3-yl)-amide;
- 5 2-phenylacetylamino-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
- 2-[2-(3-fluoro-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
- 2-[2-(3,5-bis-trifluoromethyl-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
- 5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionylamino}-1H-pyrazole-3-carboxylic
- 10 acid butyl ester;
- 2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-[5-(1H-indol-3-yl)-2H-pyrazol-3-yl]-propionamide;
- N-[5-(4-tert-butyl-phenyl)-2H-pyrazol-3-yl]-2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionamide;
- 15 2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-[5-(4-ethyl-phenyl)-2H-pyrazol-3-yl]-propionamide;
- 5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionylamino}-1H-pyrazole-3-carboxylic acid ethyl ester;
- N-(4-bromo-5-phenyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]-
- 20 propionamide;
- 1-[2-(3,5-difluoro-phenyl)-acetylamino]-cyclopentanecarboxylic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- N-(4-Chloro-5-phenyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionamide;
- 25 2-[2-(3,5-difluoro-phenyl)-acetylamino]-pent-4-enoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- [(5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionylamino}-1H-pyrazole-3-carbonyl)-amino]-phenyl-acetic acid tert-butyl ester;
- 5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionylamino}-1H-pyrazole-3-carboxylic
- 30 acid benzylamide;
- 2-[2-(3,5-difluoro-phenyl)-acetylamino]-pent-4-enoic acid (4-bromo-5-phenyl-2H-pyrazol-3-yl)-amide;
- 5-{2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionylamino}-1H-pyrazole-3-carboxylic acid methyl ester;
- 35 2-[2-(3,5-difluoro-phenyl)-acetylamino]-2-phenyl-N-(5-phenyl-2H-pyrazol-3-yl)-acetamide;

- 2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-pent-4-enoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 3-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-succinamic acid methyl ester;
- 5 2-cyclohexyl-2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-acetamide;
- 2-cyclohexyl-2-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-acetamide;
- 3-[2-(3,5-difluoro-phenyl)-2-hydroxy-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-succinamic acid benzyl ester;
- 10 2-(2-hydroxy-2-phenyl-acetylamino)-pent-4-enoic acid (5-thiophen-2-yl-2H-pyrazol-3-yl)-amide;
- 2-[2-(3,5-difluoro-phenyl)-acetylamino]-pentanoic acid (5-methyl-1-phenyl-1H-pyrazol-3-yl)-amide;
- 15 2-(2-bicyclo[2.2.1]hept-2-yl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 2-(2-cyclohexyl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 2-(3-hydroxy-2-phenyl-propionylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 20 2-(2-adamantan-1-yl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 4-methyl-pentanoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
- 3-methyl-pentanoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
- 2-(2-cyclopentyl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 2-(2-cyclopropyl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 25 2-(2-indan-2-yl-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 2-(3-phenyl-butyrylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 5-oxo-hexanoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
- 2-[2-(3-chloro-phenyl)-acetylamino]-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 2-[2-(3-bromo-phenyl)-acetylamino]-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 30 2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-(5-furan-2-yl-2H-pyrazol-3-yl)-propionamide;
- N-(5-tert-butyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionamide;
- N-(5-cyclopropyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionamide;
- 2-[2-(3,5-difluoro-phenyl)-acetylamino]-pentanoic acid (5-furan-2-yl-2H-pyrazol-3-yl)-amide;
- 35 2-[2-(3,5-difluoro-phenyl)-acetylamino]-pentanoic acid (5-thiophen-2-yl-2H-pyrazol-3-yl)-amide;

- 2-[2-(3,5-difluoro-phenyl)-acetylamino]-pentanoic acid (5-tert-butyl-2H-pyrazol-3-yl)-amide;
- 2-[2-(3,5-difluoro-phenyl)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H-pyrazol-3-yl]-amide;
- 5 N-(5-tert-butyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]-3-methylbutyramide;
- 1-[2-(3,5-difluoro-phenyl)-acetylamino]-cyclopropanecarboxylic acid (5-tert-butyl-2H-pyrazol-3-yl)-amide;
- 1-[2-(3,5-difluoro-phenyl)-acetylamino]-cyclopropanecarboxylic acid (5-furan-2-yl-2H-pyrazol-3-yl)-amide;
- 10 N-(5-biphenyl-4-yl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionamide;
- 2-[2-(3,5-difluoro-phenyl)-acetylamino]-N-[5-(3',4'-dimethyl-biphenyl-4-yl)-2H-pyrazol-3-yl]-propionamide;
- 15 2-[2-(3,5-difluoro-phenyl)-acetylamino]-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 2-phenylmethanesulfonylamino-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
- 2-(4-fluoro-phenylmethanesulfonylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
- 2-(2-nitro-phenylmethanesulfonylamino)-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
- 20 2-phenylmethanesulfonylamino-pentanoic acid (5-tert-butyl-2H-pyrazol-3-yl)-amide;
- 2-(4-fluoro-phenylmethanesulfonylamino)-pentanoic acid (5-tert-butyl-2H-pyrazol-3-yl)-amide;
- N-(5-tert-butyl-2H-pyrazol-3-yl)-2-phenylmethanesulfonylamino-propionamide;
- 2-p-tolylmethanesulfonylamino-pentanoic acid (5-tert-butyl-2H-pyrazol-3-yl)-amide;
- 25 2-phenylmethanesulfonylamino-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 2-(decane-1-sulfonylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 2-(biphenyl-4-sulfonylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 2-(4-chloro-phenylmethanesulfonylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 30 2-benzenesulfonylamino-4-methylsulfanyl-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
- 2-(4-fluoro-phenylmethanesulfonylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 2-(4,5-dichloro-thiophene-2-sulfonylamino)-4-methylsulfanyl-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide; and
- 35 2-(4-chloro-phenylmethanesulfonylamino)-pentanoic acid (5-tert-butyl-2H-pyrazol-3-yl)-amide;

- 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid benzyl-methyl-amide;
- 3,7-Dimethyl-oct-6-enoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
- 2-[2-(1-Benzyl-piperidin-3-yl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
- 5 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid dibutylamide;
- 3-[[1-(5-Phenyl-2H-pyrazol-3-ylcarbamoyl)-propylcarbamoyl]-methyl]-piperidine-1-carboxylic acid tert-butyl ester;
- 3-[[1-(5-Phenyl-2H-pyrazol-3-ylcarbamoyl)-propylcarbamoyl]-methyl]-piperidine-1-carboxylic acid tert-butyl ester;
- 10 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid ethyl-methyl-amide;
- 2-[2-(3-Chloro-phenyl)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H-pyrazol-3-yl]-amide;
- 15 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(4-phenyl-piperazine-1-carbonyl)-2H-pyrazol-3-yl]-butyramide;
- 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(2-hydroxymethyl-pyrrolidine-1-carbonyl)-2H-pyrazol-3-yl]-butyramide;
- 2-(2-Cyclohexyl-2-hydroxy-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 20 2-(2-Cyclohexyl-2-hydroxy-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(2,6-dimethyl-morpholine-4-carbonyl)-2H-pyrazol-3-yl]-butyramide;
- 25 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid (2-hydroxy-ethyl)-propyl-amide;
- 1-(5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carbonyl)-piperidine-3-carboxylic acid ethyl ester;
- 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid (2,2-dimethoxy-ethyl)-methyl-amide;
- 30 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid diethylamide;
- 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid diisobutylamide;
- 35 3,7-Dimethyl-oct-6-enoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
- 3,7-Dimethyl-oct-6-enoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;

- 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid dibenzylamide;
- 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(2-ethyl-piperidine-1-carbonyl)-2H-pyrazol-3-yl]-butyramide;
- 5 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid benzyl-ethyl-amide;
- 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid butyl-methyl-amide;
- 10 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid dihexylamide;
- 2-[2-(2,3-Difluoro-phenyl)-2-hydroxy-acetylamino]-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 2-[2-(1-Benzenesulfonyl-piperidin-3-yl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
- 15 2-[2-(1-Acetyl-piperidin-3-yl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
- 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid dipropylamide;
- 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(1-methyl-1H-benzoimidazol-2-yl)-2H-pyrazol-3-yl]-butyramide;
- 20 2-[2-(5-Bromo-pyridin-3-yl)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H-pyrazol-3-yl]-amide;
- 2-[2-(3-Trifluoromethyl-phenyl)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H-pyrazol-3-yl]-amide;
- 2-[2-(3-Methoxy-phenyl)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H-pyrazol-3-yl]-amide;
- 25 3-{1-[5-(4-Chloro-phenyl)-2H-pyrazol-3-ylcarbamoyl]-butylcarbamoyl}-5-methyl-2-propyl-hexanoic acid tert-butyl ester;
- N-(5-Phenyl-2H-pyrazol-3-yl)-2-[2-(5-phenyl-pyridin-3-yl)-acetylamino]-butyramide;
- N-(5-Phenyl-2H-pyrazol-3-yl)-2-(2-piperidin-1-yl-acetylamino)-butyramide
- 30 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid dipentylamide;
- 2-Hydroxy-hexanoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
- 2-[2-(2-Chloro-phenyl)-2-hydroxy-acetylamino]-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 35 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid (2H-pyrazol-3-yl)-amide;
- 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(5,6,7,8-tetrahydro- [1,2,4]triazolo[4,3-a]pyridin-3-yl)-2H-pyrazol-3-yl]-butyramide;

- 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-3,3-dimethyl-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
- 2-(2-Hydroxy-3-methyl-butyrylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 5 2-[2-(5-o-Tolyl-pyridin-3-yl)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H-pyrazol-3-yl]-amide;
- 2-Hydroxy-3-methyl-N-[1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-propyl]-butyramide;
- 2-[2-(2-Oxo-azepan-3-yl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
- 2-[2-(2-Oxo-azepan-3-yl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
- 10 3,7-Dimethyl-octa-2,6-dienoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
- 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid (5-methyl-2H-pyrazol-3-yl)-amide; and
- 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-hexanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 15 and pharmaceutically acceptable salts thereof.
13. A compound according to claim 12 selected from the group consisting of:
- 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-(5-furan-2-yl-2H-pyrazol-3-yl)-propionamide;
- 20 N-(5-tert-Butyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionamide;
- N-(5-Cyclopropyl-2H-pyrazol-3-yl)-2-[2-(3,5-difluoro-phenyl)-acetylamino]-propionamide;
- 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 25 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid (5-furan-2-yl-2H-pyrazol-3-yl)-amide;
- 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid (5-thiophen-2-yl-2H-pyrazol-3-yl)-amide;
- 30 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid (5-cyclopropyl-2H-pyrazol-3-yl)-amide;
- 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H-pyrazol-3-yl]-amide;
- 35 2-Phenylacetylamino-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
- 2-[2-(3-Fluoro-phenyl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;

- 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetyl-amino]-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
- 2-[2-(4-Fluoro-3-trifluoromethyl-phenyl)-acetyl-amino]-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
- 5 2-[2-(3-Phenoxy-phenyl)-acetyl-amino]-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
- 2-[2-(3,5-Difluoro-phenyl)-acetyl-amino]-pent-4-enoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetyl-amino]-4-methylsulfanyl-N- (5-phenyl-2H-pyrazol-3-yl)-butyramide;
- 10 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetyl-amino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
- 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetyl-amino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
- 5-{2-[2-(3,5-Difluoro-phenyl)-acetyl-amino]-butyrylamino}-1H-pyrazole-3-carboxylic acid ethyl ester;
- 15 5-[2-(2-Hydroxy-4-methyl-pentanoylamino)-butyrylamino]-1H-pyrazole-3-carboxylic acid ethyl ester;
- 5-{2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetyl-amino]-butyrylamino}-1H-pyrazole-3-carboxylic acid ethyl ester;
- 20 2-[2-(3,5-Difluoro-phenyl)-2-hydroxy-acetyl-amino]-N-(5-phenyl-2H-pyrazol-3-yl)-propionamide;
- N-(5-Phenyl-2H-pyrazol-3-yl)-2-(2-pyridin-3-yl-acetyl-amino)-butyramide;
- 2-[2-(5-Bromo-pyridin-3-yl)-acetyl-amino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
- 5-{2-[2-(3,5-Difluoro-phenyl)-acetyl-amino]-butyrylamino}-1H-pyrazole-3-carboxylic acid butyl-ethyl-amide;
- 25 2-[2-(3-Phenoxy-phenyl)-acetyl-amino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
- 5-{2-[2-(3,5-Difluoro-phenyl)-acetyl-amino]-butyrylamino}-1H-pyrazole-3-carboxylic acid piperidin-1-ylamide;
- 5-{2-[2-(3,5-Difluoro-phenyl)-acetyl-amino]-butyrylamino}-1H-pyrazole-3-carboxylic acid cyclohexyl-ethyl-amide;
- 30 2-(2-Cyclohexyl-acetyl-amino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 4-Methyl-pentanoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
- 3-Methyl-pentanoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
- 2-(2-Cyclopentyl-acetyl-amino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 35 2-(2-Cyclopropyl-acetyl-amino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 2-[2-(3-Chloro-phenyl)-acetyl-amino]-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 2-[2-(3-Bromo-phenyl)-acetyl-amino]-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;

- 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid benzyl-methyl-amide;
- 3,7-Dimethyl-oct-6-enoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
- 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid dibutylamide;
- 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid ethyl-methyl-amide;
- 2-(2-Cyclohexyl-2-hydroxy-acetylamino)-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(2,6-dimethyl-morpholine-4-carbonyl)-2H-pyrazol-3-yl]-butyramide;
- 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid (2-hydroxy-ethyl)-propyl-amide;
- 1-(5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carbonyl)-piperidine-3-carboxylic acid ethyl ester;
- 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid (2,2-dimethoxy-ethyl)-methyl-amide;
- 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid diisobutylamide;
- 3,7-Dimethyl-oct-6-enoic acid [1-(5-phenyl-2H-pyrazol-3-ylcarbamoyl)-butyl]-amide;
- 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid dibenzylamide;
- 2-[2-(3,5-Difluoro-phenyl)-acetylamino]-N-[5-(2-ethyl-piperidine-1-carbonyl)-2H-pyrazol-3-yl]-butyramide;
- 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid benzyl-ethyl-amide;
- 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid butyl-methyl-amide;
- 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid dihexylamide;
- 2-[2-(2,3-Difluoro-phenyl)-2-hydroxy-acetylamino]-pentanoic acid (5-phenyl-2H-pyrazol-3-yl)-amide;
- 2-[2-(1-Acetyl-piperidin-3-yl)-acetylamino]-N-(5-phenyl-2H-pyrazol-3-yl)-butyramide;
- 5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino}-1H-pyrazole-3-carboxylic acid dipropylamide;
- N-(5-Phenyl-2H-pyrazol-3-yl)-2-[2-(5-phenyl-pyridin-3-yl)-acetylamino]-butyramide;

5-{2-[2-(3,5-Difluoro-phenyl)-acetylamino]-butyrylamino]-1H-pyrazole-3-carboxylic acid dipentylamide;

2-[2-(5-o-Tolyl-pyridin-3-yl)-acetylamino]-pentanoic acid [5-(4-chloro-phenyl)-2H-pyrazol-3-yl]-amide; and

- 5 2-Hydroxy-3-methyl-N-[1-(5-phenyl-2H-pyrazol-3-yl)carbamoyl]-Butyramide;
and pharmaceutically acceptable salts thereof.

14. A pharmaceutical composition for treating in a mammal a disease or condition associated with A β -peptide production, which pharmaceutical composition comprises a compound according to claim 1 in an amount effective in inhibiting A β -
10 production, or b) in an amount effective in inhibiting said disease or condition, and a pharmaceutically acceptable carrier.

- 15 15. A method for treating in a mammal a disease or condition selected from Alzheimer's disease, hereditary cerebral hemorrhage with amyloidosis, cerebral amyloid angiopathy, a prion-mediated disease, inclusion body myositis, stroke, and Down's
Syndrome, which method comprises administering to said mammal a) an amount of a compound according to claim 1 effective in inhibiting A β -production, or b) an amount of a compound according to claim 1 effective in treating said disease or condition.

- 20 16. A method for treating dementia, including Alzheimer's disease, in a mammal, which method comprises administering to the mammal an effective amount of a compound according to claim 1 either alone or in combination with another drug, either separately or as part of a single pharmaceutical composition, wherein the other drug is selected from a memory enhancement agent, an antidepressant agent, an anxiolytic, an antipsychotic agent, a sleep disorder agent, an anti-inflammatory agent, an anti-oxidant agent, a cholesterol modulating agent, or an anti-hypertension agent.